How Retatrutide Compares to Mounjaro
Understanding the new weight loss drugs is key. Many ask How Retatrutide Compares to Mounjaro. Both are from Eli Lilly. But they work differently.
Mounjaro is a dual-hormone drug. Retatrutide is a triple-hormone drug. This is the main difference.
This guide will break it down. We’ll look at how they work. We will review their results. We will also cover side effects.
Mechanism of Action: The Core Difference
The main difference is in their design. Mounjaro targets two hormone pathways. Retatrutide targets three.
Mounjaro: The Dual Agonist
Mounjaro’s drug name is tirzepatide. It mimics two gut hormones. These are GIP and GLP-1.
GLP-1 slows stomach emptying. This makes you feel full. It also reduces appetite in the brain.
GIP boosts insulin secretion. It may help with fat metabolism. It might also reduce nausea.
Together, they are very powerful. This made Mounjaro a top drug.
Retatrutide: The Triple Agonist
Retatrutide is the next step. It mimics three hormones. These are GIP, GLP-1, and glucagon.
The first two work like Mounjaro. The third is the key addition.
Glucagon is a game-changer. It tells the body to burn more energy. It increases calorie burn at rest.
This triple action aims for greater effect. It targets appetite, insulin, and metabolism together.
Efficacy: Weight Loss Results
Direct comparison trials are not done. But we can look at their separate studies. The results show a clear trend.
Mounjaro’s Weight Loss Data
Mounjaro was tested in the SURMOUNT-1 trial. People with obesity took it for 72 weeks.
The results were impressive. The highest dose (15mg) led to 20.9% weight loss on average. This set a new standard at the time.
Retatrutide’s Weight Loss Data
Retatrutide’s Phase 2 trial was shocking. People took it for 48 weeks.
The mid-dose (8mg) led to 17.5% weight loss. The high dose (12mg) led to 24.2% weight loss.
This was a new record. About 30% of people lost over 30% of their weight.
Extension data is even more promising. Weight loss continued past 48 weeks. It shows Retatrutide’s powerful potential.
Efficacy Verdict: Retatrutide shows higher weight loss in trials. The glucagon effect adds significant power.
Safety and Side Effects
More power can mean more side effects. Both share a common profile. But Retatrutide has unique notes.
Common Gastrointestinal Issues
Both drugs cause GI side effects. This is due to the GLP-1 action.
Common issues include nausea and diarrhea. Constipation and vomiting can also occur.
These effects are usually worst at the start. They often fade as the body adjusts.
Unique Notes for Retatrutide
The glucagon part changes things. It increases metabolic rate.
This led to two notable effects in trials. First, a rise in resting heart rate. Second, a slight rise in blood pressure.
Weight loss usually lowers blood pressure. This can offset the drug’s direct effect.
There is also a brief blood sugar rise early on. This is due to glucagon’s action. It is later overcome by weight loss and better insulin sensitivity.
Safety Verdict: Mounjaro has a known, manageable profile. Retatrutide seems similar for GI issues.
But it requires watchful monitoring for heart rate and blood pressure. Its full safety profile is still under study.
Dosage and Administration
Both are once-weekly injections. They use similar auto-injector pens.
A slow dose increase is critical. This helps manage stomach side effects.
Mounjaro’s maintenance doses are 5mg, 10mg, or 15mg. Retatrutide’s tested doses were 4mg, 8mg, and 12mg.
Final commercial doses for Retatrutide may differ. This depends on Phase 3 trial results.
Availability and Status
This is a major practical difference.
Mounjaro is FDA-approved. It is available for type 2 diabetes. Its weight loss version is called Zepbound.
Both are available now with a prescription.
Retatrutide is not approved. It is still an investigational drug. It is only available in clinical trials.
Its approval is expected, but timing is unsure.
The Bottom Line
So, how does Retatrutide compare to Mounjaro?
Mounjaro is a current, proven leader. It is a powerful dual-hormone drug. It is available today.
Retatrutide is the promising future. It is a triple-hormone drug. It aims for even greater weight loss.
The choice isn’t really one or the other yet. Mounjaro is the established option. Retatrutide represents the next potential leap.
For now, Mounjaro (and Zepbound) are real tools. Retatrutide is a very hopeful horizon. Both show amazing progress in treating obesity.